To help address public health needs amidst the evolving COVID-19 pandemic, Mylan has restarted production of hydroxychloroquine sulfate tablets at its West Virginia manufacturing facility in the U.S. to meet the potential for increased demand resulting from potential effectiveness of the product in treating COVID-19.   Mylan’s hydroxychloroquine sulfate tablets are approved by the U.S. FDA for the treatment of malaria, lupus erythematosus and rheumatoid arthritis. Although the product is n...